Novartis Advances Novel Kidney Disease Therapy Iptacopan
Data Suggest Promise For Lead Nephrology Asset
Executive Summary
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
You may also be interested in...
AstraZeneca Hopes Danicopan Interim Data Will Prove Sufficient For NDA Filing
Danicopan seen as potential add-on therapy for paroxysmal nocturnal hemoglobinuria patients getting suboptimal results from Soliris or Ultomiris therapy. AstraZeneca will investigate filing for approval on 12-week data.
Apellis’ Empaveli Data In Frontline PNH Incremental, But Still Helpful
While the drug appears more efficacious than Alexion’s C5 inhibitors, those drugs could prove difficult to dethrone given how entrenched they are in PNH therapy.
Novartis CEO Touts R&D 'Wild Cards' As Proof Of Deep Pipeline
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.